FDA panel to discuss Acadia's Nuplazid for PDP

FDA's Psychopharmacologic Drugs Advisory Committee will meet on March 29 to discuss an NDA for Nuplazid pimavanserin from Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) to treat Parkinson's disease psychosis. The NDA is under Priority Review with a PDUFA date of May 1. ...